Table 1.
The Correlation Between GSN Expression and Prognosis in GC with Respect to Clinicopathological Factors
| Clinicopathological | Overall Survival | Progression-Free Survival | ||||
|---|---|---|---|---|---|---|
| N | Hazard Ratio | P-value | N | Hazard Ratio | P-value | |
| SEX | ||||||
| Female | 244 | 1.58 (1.1–2.27) | 0.013 | 201 | 1.29 (0.86–1.92) | 0.21 |
| Male | 566 | 1.2 (0.96–1.49) | 0.11 | 437 | ||
| STAGE | ||||||
| 1 | 67 | 1.92 (0.72–5.15) | 0.19 | 60 | 3.14 (0.41–24.33) | 0.25 |
| 2 | 140 | 2.11 (1.16–3.86) | 0.013 | 131 | 1.44 (0.79–2.63) | 0.23 |
| 3 | 305 | 1.41 (1.05–1.88) | 0.021 | 186 | 1.26 (0.84–1.9) | 0.26 |
| 4 | 148 | 1.88 (1.17–3.04) | 0.0086 | 141 | 1.74 (1.06–2.84) | 0.026 |
| STAGE T | ||||||
| 2 | 241 | 1.45 (0.87–2.41) | 0.15 | 239 | 1.32 (0.79–2.18) | 0.29 |
| 3 | 204 | 1.55 (1.08–2.21) | 0.015 | 204 | 1.54 (1.1–2.18) | 0.013 |
| 4 | 38 | 2.41 (1–5.82) | 0.045 | 39 | 2.29 (1.01–5.2) | 0.043 |
| STAGE N | ||||||
| 0 | 74 | 3.53 (1.04–11.94) | 0.031 | 72 | 3.48 (1.03–11.79) | 0.033 |
| 1 | 225 | 1.34 (0.89–2.02) | 0.16 | 222 | 1.28 (0.87–1.89) | 0.21 |
| 2 | 121 | 1.38 (0.85–2.25) | 0.19 | 125 | 1.26 (0.79–2.02) | 0.33 |
| 3 | 76 | 3.28 (1.46–7.4) | 0.0026 | 76 | 2.64 (1.17–5.97) | 0.016 |
| 1+2+3 | 422 | 1.48 (1.12–1.95) | 0.0056 | 423 | 1.35 (1.05–1.74) | 0.021 |
| STAGE M | ||||||
| 0 | 444 | 1.47 (1.11–1.93) | 0.0063 | 443 | 1.4 (1.07–1.82) | 0.013 |
| 1 | 56 | 2.5 (1.14–5.49) | 0.019 | 56 | 2.24 (1.01–4.97) | 0.042 |
| LAUREN CLASSIFICATION | ||||||
| Intestinal | 320 | 1.44 (1.05–1.99) | 0.023 | 263 | 1.29 (0.85–1.94) | 0.22 |
| Diffuse | 241 | 1.67 (1.17–2.4) | 0.0048 | 231 | 1.78 (1.24–2.55) | 0.0015 |
| DIFFERENTIATIN | ||||||
| Poor | 165 | 0.83 (0.56–1.24) | 0.36 | 121 | 1.66 (0.93–2.98) | 0.084 |
Abbreviation: N, number.